Publications
Detailed Information
Breast Cancer: Early Prediction of Response to Neoadjuvant Chemotherapy Using Parametric Response Maps for MR Imaging
Cited 70 time in
Web of Science
Cited 79 time in Scopus
- Authors
- Issue Date
- 2014-08
- Publisher
- Radiological Society of North America
- Citation
- Radiology, Vol.272 No.2, pp.385-396
- Abstract
- Purpose: To prospectively compare the performance of dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging using parametric response map (PRM) analysis with that using pharmacokinetic parameters (transfer constant [K-trans], rate constant [k(ep)], and relative extravascular extracellular space [v(e)]) in the early prediction of pathologic responses to neoadjuvant chemotherapy (NAC) in breast cancer patients. Materials and Methods: The institutional review board approved this study; informed consent was obtained. Between August 2010 and December 2012, 48 women (mean age, 46.4 years; range, 29-65 years) with breast cancer were enrolled and treated with an anthracycline-taxane regimen. DCE MR imaging was performed before and after the first cycle of chemotherapy, and the pathologic response was assessed after surgery. Tumor size and volume, PRM characteristics, and pharmacokinetic parameters (K-trans, k(ep), and v(e)) on MR images were assessed and compared according to the pathologic responses by using the Fisher exact test or the independent-sample t test. Results: Six of 48 (12%) patients showed pathologic complete response (CR) (pCR) and 42 (88%) showed nonpathologic CR (npCR). Thirty-eight (79%) patients showed a good response (Miller-Payne score of 3, 4, or 5), and 10 (21%) showed a minor response (Miller-Payne score of 1 or 2). The mean proportion of voxels with increased signal intensity (PRMSI+) in the pCR or good response group was significantly lower than that in the npCR or minor response group (14.0% +/- 6.5 vs 40.7% +/- 27.2, P < .001; 34.3% +/- 26.4 vs 52.8% +/- 24.9, P =.041). Area under the receiver operating characteristic curve for PRMSI+ in the pCR group was 0.770 (95% confidence interval: 0.626, 0.879), and that for the good response group was 0.716 (95% confidence interval: 0.567, 0.837). No difference in tumor size, tumor volume, or pharmacokinetic parameters was found between groups. Conclusion: PRM analysis of DCE MR images may enable the early identification of the pathologic response to NAC after the first cycle of chemotherapy, whereas pharmacokinetic parameters (K-trans, k(ep), and v(e)) do not. (C) RSNA, 2014
- ISSN
- 0033-8419
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.